Sur­vey says drug com­mer­cial­iza­tion should stretch back, in­cor­po­rate dig­i­tal in­sights for doc­tors

The best time for phar­ma com­pa­nies to start talk­ing to doc­tors about a new drug is about 18 months be­fore launch, ac­cord­ing to new sur­vey da­ta.

While that may sound like a long time out, and well be­fore the FDA has weighed in on whether the drug is a go or no-go, it’s what sur­faced from physi­cians’ in­ter­views and sur­veys in PRE­CI­SION­ef­fect’s lat­est quar­ter­ly plat­form da­ta.

“Doc­tors are aware of what’s hap­pen­ing at the FDA and they’re aware what phar­ma is al­lowed to do and what they’re not al­lowed to do. But around that crit­i­cal point be­tween Phase II and Phase III, doc­tors want to start hear­ing from the com­pa­ny around the sci­ence,” said John Fitz­patrick, SVP of om­nichan­nel en­gage­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER